Daiichi Sankyo replaces head of its Ranbaxy unit

New Delhi Mon May 25, 2009 1:26pm IST

Malvinder Singh speaks during a news conference in New Delhi in this June 11, 2008 file photo. REUTERS/Danish Ismail/Files

Malvinder Singh speaks during a news conference in New Delhi in this June 11, 2008 file photo.

Credit: Reuters/Danish Ismail/Files

Related Topics

New Delhi (Reuters) - Japanese drugmaker Daiichi Sankyo said Malvinder Singh, chairman and chief executive of its Indian unit Ranbaxy Laboratories, had resigned and named replacements for him on Sunday.

On May 12, Japan's third-biggest drugmaker forecast its full-year profit would be well below expectations, blaming losses at Ranbaxy and saying it planned to get actively involved in resolving its unit's problems.

Non-executive director Tsutomu Une was named chairman while Atul Sobti, Ranbaxy's chief operating officer, was promoted to chief executive and managing director.

New chairman Une told reporters the move was aimed at "accelerating growth" of Ranbaxy. "The separation was amicable."

Ranbaxy has been hit by a U.S. ban on some products for alleged falsification of data, and by foreign exchange hedges being hit by a weaker rupee.

Last year, Daiichi Sankyo bought a 63.9 percent stake, including the founders' entire stake, in Ranbaxy, aiming to take advantage of rising demand for generic drugs.

But the stake lost more than two thirds of its value by the end of financial year primarily hit by the weak rupee and the U.S. FDA ban. Last month, Ranbaxy forecast a loss of $150 million in 2009, on a 9 percent fall in sales to $1.4 billion.

Ranbaxy and Daiichi Sankyo have said they are working with the U.S. FDA, and new CEO Sobti said the company was on track to meet with the FDA soon. The firm also said there was no plan to delist Ranbaxy.

Malvinder Singh's exit came within a year of selling the company his grandfather began building half a century ago.

"It was a difficult decision to separate from Ranbaxy," said Singh, who took over as chief executive in 2006.

Earlier, the Economic Times daily said Singh's tenure at the helm was scheduled to end in 2013 and he was entitled to a severance package of 450 million rupees ($9.6 million) if he left the company before. Une, when asked about the severance package, said the company would proceed according to the employment agreement. He did not elaborate.

Ranbaxy shares are down 12.5 percent so far in 2009 compared with a 44 percent rise in the benchmark index

($1 = 47.1 rupees)

FILED UNDER:

Monetary Policy Committee

Reuters Showcase

Microfinance

Microfinance

Funding the unfunded: India helps small business borrow to grow  Full Article 

Insurance Sector

Insurance Sector

UK healthcare firm Bupa sees strong growth in India  Full Article 

Sensex Rises

Sensex Rises

Sensex edges up; consumer and healthcare stocks rise  Full Article 

Market Eye

Market Eye

FTSE adds nine Indian firms as large-caps in Asia-Pacific ex-Japan index   Full Article 

Indian Ocean Diplomacy

Indian Ocean Diplomacy

PM Modi to ramp up help for Indian Ocean nations to counter China influence  Full Article 

ECB Bond-Buying

ECB Bond-Buying

ECB raises growth forecasts, to start printing money next week  Full Article 

China Economy

China Economy

China signals "new normal" with lower annual growth target  Full Article 

Pharma Sector

Pharma Sector

Panel recommends waiving late-stage trials for some drugs  Full Article 

E-commerce

E-commerce

China backs e-commerce expansion in win for Alibaba, JD.com  Full Article 

Reuters India Mobile

Reuters India Mobile

Get the latest news on the go. Visit Reuters India on your mobile device  Full Coverage